Feeding Change is a team of food-system experts within the Milken Institute, a nonprofit, nonpartisan think tank, who activate social and financial capital, engage policymakers and industry leaders, and convene key stakeholders to catalyze a more nutritious, sustainable, resilient, and equitable food system. Sitting at the intersection of finance and health, Feeding Change is uniquely positioned within the Milken Institute to provide expertise on how to leverage the Farm Bill to drive food systems transformation and achieve better health outcomes. Improving health outcomes will help reduce the prevalence and severity of chronic health conditions, which drive the greatest portion of healthcare costs.
Feeding Change worked with key stakeholders to inform the policy priorities in this document. These stakeholders include members from the Feeding Change Food Is Medicine (FIM) Task Force (an advisory group of nonprofit and academic FIM experts) and a Business Council of food systems leaders. These members represent over 50 companies and organizations across the insurance, health system, food retail, academic, nonprofit, technology, investment, agriculture, and food processing and manufacturing sectors. View a full list of FIM Task Force members and advisors.

Ilana Moreno

Holly Freishtat

Athena Rae Roesler
Related Content
-
Milken Institute Future of Health Summit Opens Tomorrow, June 22
Washington, DC – June 21, 2021 – The Milken Institute Future of Health Summit kicks off tomorrow, drawing more than 1,000 leaders from government, academia, business, philanthropy, tech, and the private sector. Over the course of two days...Read Article -
Tracking What Matters: How to Address Critical WIC Needs during a Public Health Emergency
Explore Tracker This report analyzes the COVID-19 waiver process for the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) state agencies during the initial stage of the COVID-19 pandemic. In response to COVID-19...Read Report11 11
Athena Rae Roesler, Niyeti Shah, and Care Shoaibi -
A National Network to Advance Innovative Financing for Women’s Reproductive Health
This report examines innovative financing and partnership models that could be used to fill gaps to scale innovation and deliver equitable, high-quality care across research and development, infrastructure, products, and services for women...Read Report -
Expiration of the Public Health Emergency for COVID-19
Submitted electronically The Honorable Xavier Becerra Secretary US Department of Health & Human Services Washington, DC 20201 On behalf of the Milken Institute, I write to share our insights and suggestions pertaining to the forthcoming...Read LetterImageEsther Krofah
Executive Vice President, Milken Institute HealthEsther Krofah is the executive vice president of Milken Institute Health, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives. -
Models for Financing Antibiotic Development to Address Antimicrobial Resistance
The Financial Innovations Labs® and FasterCures teams have collaborated on a project to identify new models for financing the antimicrobial resistant antibiotic pipeline. These past 18 months have demonstrated how consequential public...Read Report11
-
Milken Institute Advisory Council Roundtable on Preventative Health
DOWNLOAD REPORT Each year, the United Kingdom National Health Service (NHS) treats more patients for preventable diseases, yet funding remains largely focused on hospital care rather than prevention. Without new investment in preventative...Read Report11
11
-
Health Policy Leader Esther Krofah Named Executive Director of FasterCures
WASHINGTON, March 4, 2020 – Esther Krofah, a respected leader in biomedical research, development, and public policy, has been named executive director of FasterCures, the Milken Institute center devoted to accelerating access to life...Read ArticleImageJeff Valliere
Executive Vice President and Chief Strategy OfficerJeff Valliere oversees the development of fully integrated, strategic initiatives that support the mission, vision, and values of the Milken Institute. -
From Recovery to Resilience: How Opportunity Zones Can Help Accelerate Post-COVID Economic Resurgence
The COVID-19 pandemic presents an unprecedented challenge to all economies. However, pandemics hit underserved and vulnerable populations the hardest, and now the crisis will exacerbate their need for capital. Opportunity Zones—which...Read Report11
Dan Carol and Ragini Chawla -
Pandemic and All-Hazards Preparedness Act (PAHPA) Policy Brief
The Milken Institute Center for Public Health and FasterCures have identified three PAHPA 2023 policy priorities that are core to improving and strengthening the nation’s biosecurity and preparedness infrastructure. These priorities are...Read Brief -
Milken Institute Statement on ARPA-H Inclusion in FY2022 Spending Bill
FasterCures, a Center of the Milken Institute, is pleased to see the inclusion of $1 billion in funding for a new Advanced Research Projects Agency for Health (ARPA-H) in the omnibus FY22 spending bill recently passed. We have long...Read StatementImageEsther Krofah
Executive Vice President, Milken Institute HealthEsther Krofah is the executive vice president of Milken Institute Health, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives. -
Lessons Learned From COVID-19: Are There Silver Linings for Biomedical Innovation?
FasterCures wants to ensure that the lessons of the COVID-19 crisis are not lost once the current urgency subsides — not only for combating future infectious diseases, but for conducting every other aspect of biomedical innovation...Read Report -
Distance as an Obstacle to Clinical Trial Access: Who Is Affected and Why It Matters
Access to clinical trials is valuable for patients as it provides the possibility to obtain novel treatments that are not yet commercially available. There are many barriers to access for patients wishing to join clinical trials, including...View Research11